Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan and Abraxane in Inoperable Stage III and IV Malignant Melanoma
NCT02142335Phase 2Unknown
- Sponsor
- cCARE
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, nab-paclitaxel in Malignant Melanoma (MM), sponsored by cCARE. Status: unknown.
02
Drugs
rituximabnab-paclitaxel
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02142335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142335.